YS Biopharma Co., Ltd.
YS · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $554,737 | $560,464 | $850,662 | $1,816,634 |
| - Cash | $28,084 | $246,351 | $370,108 | $885 |
| + Debt | $414,401 | $424,465 | $498,630 | $380,589 |
| Enterprise Value | $941,054 | $738,578 | $979,184 | $2,196,338 |
| Revenue | $614,962 | $573,418 | $687,201 | $502,950 |
| % Growth | 7.2% | -16.6% | 36.6% | – |
| Gross Profit | $507,189 | $455,730 | $533,841 | $385,884 |
| % Margin | 82.5% | 79.5% | 77.7% | 76.7% |
| EBITDA | -$48,538 | -$368,663 | -$76,800 | -$67,196 |
| % Margin | -7.9% | -64.3% | -11.2% | -13.4% |
| Net Income | -$99,982 | -$433,465 | -$145,479 | -$546 |
| % Margin | -16.3% | -75.6% | -21.2% | -0.1% |
| EPS Diluted | -0.94 | -4.05 | -1.88 | -0.019 |
| % Growth | 76.8% | -115.4% | -10,062.2% | – |
| Operating Cash Flow | -$120,982 | -$295,230 | -$182,469 | -$613 |
| Capital Expenditures | -$17,859 | -$44,251 | -$57,050 | -$298,932 |
| Free Cash Flow | -$138,840 | -$339,480 | -$239,519 | -$299,545 |